drugset / Trial / NCT02289768

Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses

NCT02289768

Phase 3 Completed 166 enrolled Almirall, S.A. Almirall Hermal GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this vehicle-controlled study is to determine the efficacy and safety of a solution of Actikerall® (containing 5-fluorouracil 0.5% and salicylic acid 10.0%) in the field-directed treatment of grade I-II actinic keratosis, when it is applied to the affected area once daily for 12 weeks. A secondary objective of this study is to evaluate the efficacy of Actikerall® solution on subclinical actinic keratosis lesions in a subset of patients.

Timeline

Start
2014-10
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject fluorouracil Small molecule 0.5 % Topical
Subject salicylic acid Small molecule 10 % Topical

Indications